Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants
By Elana Gotkine HealthDay Reporter
FRIDAY, June 21, 2024 -- The cumulative risk for advanced gastric cancer varies from 6.5 to 10.3 percent for carriers of germline CDH1 pathogenic/likely pathogenic (P/LP) variants, according to a study published online June 14 in the Journal of the American Medical Association to coincide with presentation at the International Gastric Cancer Linkage Consortium, held from June 13 to 15 in Porto, Portugal.
Carrie E. Ryan, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues describe gastric and breast cancer risk estimates for individuals with CDH1 variants in a multicenter retrospective cohort and modeling study. Data were included from 213 families from North America with a germline CDH1 P/LP variant; 883 of the 7,323 individuals had a CDH1 P/LP variant.
The researchers found that the prevalence of gastric cancer was 13.9 percent among those with a CDH1 P/LP variant, and the prevalence of breast cancer was 26.3 percent among female carriers. The estimated hazard ratio for advanced gastric cancer was 33.5 and 3.5 at ages 30 and 70 years, respectively. In male and female carriers, the lifetime cumulative risk for advanced gastric cancer was 10.3 and 6.5 percent, respectively. A carrier with three affected first-degree relatives had a penetrance of about 38 percent in gastric cancer risk estimates based on family history. The hazard ratio for breast cancer among female carriers was 5.7 and 3.9 at ages 30 and 70 years, respectively; the lifetime cumulative risk for breast cancer was 36.8 percent among female carriers.
"These findings inform current management of individuals with germline CDH1 variants," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
FDA Approves Datroway for HR-Positive, HER2-Negative Breast Cancer
FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic, hormone...
Adjuvant Trastuzumab Emtansine Improves Overall Survival in HER2+ Breast Cancer
THURSDAY, Jan. 16, 2025 -- For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall...
AI-Supported Double Mammogram Reading Improves Detection Rate
TUESDAY, Jan. 14, 2025 -- Artificial intelligence (AI)-supported double-reading mammography is associated with a higher breast cancer detection rate, without affecting the recall...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.